The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Secondary efficacy subanalysis by histology from the phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL).
Ian Flinn
Research Funding - Teva
Richard H. C. Van Der Jagt
Consultant or Advisory Role - Lundbeck; Teva
Honoraria - Celgene; Novartis; Roche
Research Funding - Celgene; Cell Therapeutics; Lundbeck; Roche; Teva
Brad S. Kahl
Consultant or Advisory Role - Genentech; Teva
Research Funding - Genentech
Peter Wood
No relevant relationships to disclose
Tim E. Hawkins
No relevant relationships to disclose
David MacDonald
Consultant or Advisory Role - Lundbeck; Roche
Mark Hertzberg
No relevant relationships to disclose
Yiu-Lam Kwan
No relevant relationships to disclose
David Simpson
No relevant relationships to disclose
Michael Craig
No relevant relationships to disclose
Kathryn S. Kolibaba
Research Funding - Pharmacyclics
Samar Issa
No relevant relationships to disclose
Regina Clementi
Employment or Leadership Position - Teva
Stock Ownership - Teva
Doreen M. Hallman
Employment or Leadership Position - Teva
Mihaela C. Munteanu
Employment or Leadership Position - Teva
Stock Ownership - Teva
Ling Chen
Employment or Leadership Position - Teva
Stock Ownership - Teva
John M. Burke
Consultant or Advisory Role - Alexion Pharmaceuticals; Dendreon; Genomic Health; Seattle Genetics; Spectrum Pharmaceuticals